Skip to main content
Premium Trial:

Request an Annual Quote

HistoRx Licenses Melanoma Assay from Yale

NEW YORK (GenomeWeb News) – HistoRx today said that it has licensed from Yale University a new melanoma assay based on the Aqua technology invented at Yale.

Branford, Conn.-based HistoRx said the licensed assay will enable physicians to identify a subset of patients who despite having no detectable cancer in their lymph nodes have a 40 percent risk of recurrence of their disease. The prognostic assay was developed by David Rimm, inventor of the underlying Aqua technology and the director of pathology tissue services at the Yale School of Medicine.

The Aqua technology is an automated, quantitative immunohistochemistry testing method that enables measurement of protein biomarkers in tissue.

The test contains five biomarkers and provides results intended to delineate between low-risk and high-risk patients.

HistoRx said the test also may be useful in guiding treatment decisions for Stage II, node-negative melanoma patients.

Terms of the licensing agreement were not disclosed.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.